Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Shanton Pharma General Information
In March 2025, Shanton Pharma reported positive topline data from their Phase IIb study, indicating that SAP-001 met its primary endpoint by significantly reducing serum urate levels in refractory gout patients[5]. The RID GOUT Study was a six-month, multi-center, randomized, double-blind, placebo-controlled study that enrolled 87 patients across 21 U.S. sites[5].
Contact Information
Drug Pipeline
SAP-001
Phase 2Key Partnerships
Shanton Pharma Funding
No funding data available
To view Shanton Pharma's complete valuation and funding history, request access »